ChemIDplus Advanced United States National Library of Medicine Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp. Note: Compound name must be entered under "Substance Identification" and then "Names and Synonyms" selected to view synonyms.
Ampyra (dalfampridine) medication guide Therapeutics A, 2011 Accessed on 4 Jan 2012 from http://ampyra.com/medication_guide/.
Emerging oral agents for multiple sclerosis. Fox EJ Am J Manag Care. 2010 Sep; 16(8 Suppl):S219-26. PMID: 20873946. Abstract
Dose comparison trial of sustained-release fampridine in multiple sclerosis. Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, Cohen R, Marinucci LN, Blight AR, Fampridine MS-F202 Study Group Neurology. 2008 Oct 7; 71(15):1134-41. Epub 2008 Jul 30. PMID: 18672472. Abstract
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR, Fampridine MS-F203 Investigators Lancet. 2009 Feb 28; 373(9665):732-8. PMID: 19249634. Abstract
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR, MSF204 Investigators Ann Neurol. 2010 Oct; 68(4):494-502. PMID: 20976768. Abstract
Voltage-gated potassium channels in multiple sclerosis: Overview and new implications for treatment of central nervous system inflammation and degeneration. Judge SIV, Lee JM, Bever CT, Hoffman PM J Rehabil Res Dev. 2006 Jan-Feb; 43(1):111-22. PMID: 16847777. Abstract
FDA approves Ampyra to improve walking in adults with multiple sclerosis FDA, 22 Jan 2010 Accessed on 4 Jan 2012 from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm198463.htm.
Biogen Idec receives negative opinion from the CHMP on Fampyra Idec B, 21 Jan 2011 Accessed on 4 Jan 2012 from http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1518474.
Function and distribution of three types of rectifying channel in rat spinal root myelinated axons. Baker M, Bostock H, Grafe P, Martius P J Physiol. 1987 Feb; 383:45-67. PMID: 2443652. Abstract
Therapeutic class review, Neurological - multiple sclerosis dalfampridine (Ampyra(TM)) RegenceRx, Jun 2010 Accessed on 4 Jan 2012 from www.regencerx.com/docs/physicianRx/neurological-ampyra-0610.pdf.
European medicines agency's committee for medicinal products for human use issues positive opinion on marketing authorisation application for Fampyra Biogen Idec, 20 May 2011 Accessed on 4 Jan 2012 from http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1566089.
Treatment of walking impairment in multiple sclerosis with dalfampridine. Blight AR Ther Adv Neurol Disord. 2011 Mar; 4(2):99-109. PMID: 21694807. Abstract
Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis. Jeffery DR, Pharr E P Core Evid. 2010; 5:107-12. Epub 2010 Dec 08. PMID: 21468366. Abstract
Extoxnet (extension toxicology network), 4-aminopyridine Pesticide Information Project of Cooperative Extension Offices of Cornell University, Sep 1993 Accessed on 4 Jan 2012 from http://pmep.cce.cornell.edu/profiles/extoxnet/24d-captan/4aminopyridine-ext.html.
Ampyra (Fampyra) Multiple Sclerosis Resource Centre, 11 Apr 2011 Accessed on 4 Jan 2012 from http://www.msrc.co.uk/index.cfm/fuseaction/show/pageid/1310.
Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits Acorda Therapeutics, 12 Jun 2012 Accessed on 12 Jun 2012 from http://ir.acorda.com/phoenix.zhtml?c=194451&p=irol-newsOtherArticle&ID=1704402&highlight=.
Clinical overview of the seizure risk of dalfampridine. Haut SR, Bienen JE, Miller A Expert Opin Drug Saf. 2012 Jul; 11(4):651-7. Epub 2012 Jun 18. PMID: 22703551. Abstract
FDA warns about seizures linked to MS drug Clarke T, MSNBC.com, 23 Jul 2012 Accessed on 30 Jul 2012 from http://www.msnbc.msn.com/id/48288454/ns/health-health_care/#.UBauZu26S-J.
Fampridine – Benefit assessment according to § 35a Social Code Book V Institute for Quality and Efficiency in Health Care, 26 Apr 2012 Accessed on 4 Sep 2012 from https://www.iqwig.de/download/A12-06_Fampridine_Extract_of_dossier_assessment.pdf.
Added benefit of fampridine is not proven Science Codex, 29 Aug 2012 Accessed on 5 Sep 2012 from http://www.sciencecodex.com/added_benefit_of_fampridine_is_not_proven-97483.
Acorda Therapeutics announces top line results of post-marketing commitment study exploring 5 mg dose of dalfampridine-ER Acorda Therapeutics, 13 Aug 2012 Accessed on 5 Sep 2012 from http://ir.acorda.com/phoenix.zhtml?c=194451&p=irol-newsOtherArticle&ID=1724941&highlight=.
Ampyra 10mg beats 5mg, but weak overall results net neutral for ACOR Reuters, 13 Aug 2012 Accessed on 5 Sep 2012 from http://www.reuters.com/article/2012/08/13/idUS125391+13-Aug-2012+HUG20120813.
AMPYRA® two-year safety data presented at 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Acorda Therapeutics, 10 Oct 2012 Accessed on 16 Oct 2012 from http://ir.acorda.com/phoenix.zhtml?c=194451&p=irol-newsOtherArticle&ID=1743556.
Acorda Therapeutics announces Hatch-Waxman extension of AMPYRA® (dalfampridine) sustained-release formulation patent Acorda Therapeutics, 16 Oct 2012 Accessed on 1 Nov 2012 from http://ir.acorda.com/phoenix.zhtml?c=194451&p=irol-newsOtherArticle&ID=1745632.
Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report. Schniepp R, Jakl V, Wuehr M, Havla J, Kümpfel T, Dieterich M, Strupp M, Jahn K Mult Scler. 2012 Oct 15. PMID: 23069878. Abstract
Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with MS. Weir S, Gao Y, Henney HR Curr Med Res Opin. 2012 Nov 16. PMID: 23157466. Abstract
Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with MS. Weir S, Torkin R, Henney HR Curr Med Res Opin. 2012 Nov 16. PMID: 23157467. Abstract
Inhibition of Neuronal Degenerin/Epithelial Na+ Channels by the Multiple Sclerosis Drug 4-Aminopyridine. Boiko N, Kucher V, Eaton BA, Stockand JD J Biol Chem. 2013 Feb 12. PMID: 23404498. Abstract
4-aminopyridine toxicity: a case report and review of the literature. King AM, Menke NB, Katz KD, Pizon AF J Med Toxicol. 2012 Sep; 8(3):314-21. PMID: 22782458. Abstract
Acorda Therapeutics announces positive AMPYRA® (dalfampridine) Phase 2 data in people with post-stroke deficits Acorda Therapeutics, 15 Apr 2013 Accessed on 26 Apr 2013 from http://ir.acorda.com/phoenix.zhtml?c=194451&p=irol-newsOtherArticle&ID=1806488.
Editors' Pick Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy. Horton L, Conger A, Conger D, Remington G, Frohman T, Frohman E, Greenberg B Neurology. 2013 Apr 24. Epub 1969 Dec 31. PMID: 23616154. Abstract
Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US. Jara M, Barker G, Henney HR Neuropsychiatr Dis Treat. 2013; 9:365-70. Epub 2013 Mar 10. PMID: 23662056. Abstract
Dalfampridine Improves Sensorimotor Function in Rats With Chronic Deficits After Middle Cerebral Artery Occlusion. Iaci JF, Parry TJ, Huang Z, Finklestein SP, Ren J, Barrile DK, Davenport MD, Wu R, Blight AR, Caggiano AO Stroke. 2013 May 7. PMID: 23652269. Abstract
Acorda Therapeutics announces issuance of additional U.S. Patent for AMPYRA® covering a range of dosage strengths Acorda Therapeutics, 20 May 2013 Accessed on 21 May 2013 from http://ir.acorda.com/phoenix.zhtml?c=194451&p=irol-newsOtherArticle&ID=1821937.
4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis. Göbel K, Wedell J-H, Herrmann AM, Wachsmuth L, Pankratz S, Bittner S, Budde T, Kleinschnitz C, Faber C, Wiendl H, et al. Exp Neurol. 2013 Jun 5; 248C:62-71. PMID: 23748135. Abstract
Estimation of the effect of dalfampridine on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients. Limone BL, Sidovar MF, Coleman CI Health Qual Life Outcomes. 2013 Jun 26; 11(1):105. Epub 2013 Jun 26. PMID: 23799913. Abstract
Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function. Rabadi MH, Kreymborg K, Vincent AS Drugs R D. 2013 Jul 20. PMID: 23873597. Abstract
Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study. Cameron MH, Overs S, Murchison C, Whitham R, Fitzpatrick M, Manning J Mult Scler. 2013 Oct 7. PMID: 24099749. Abstract
Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open-label study. Samara E, Winkle P, Pardo P, Henney HR, Way SL, Brown E, Lee A, Blight AR J Clin Pharmacol. 2013 Sep 30. PMID: 24150835. Abstract
Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases. Prugger M, Berger T Patient Relat Outcome Meas. 2013; 4:75-85. Epub 2013 Oct 23. PMID: 24187513. Abstract
Long-term effects of dalfampridine in patients with multiple sclerosis. Ruck T, Bittner S, Simon OJ, Göbel K, Wiendl H, Schilling M, Meuth SG J Neurol Sci. 2013 Nov 16. PMID: 24290498. Abstract
Oral dalfampridine improves standing balance detected at static posturography in multiple sclerosis. Prosperini L, Giannì C, Fortuna D, Marchetti M R, Pozzilli C Mult Scler Int. 2014; 2014:802307. Epub 2014 Mar 27. PMID: 24800078. Abstract
Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose. Ballesta Méndez M, van Pesch V, Capron A, Hantson P Case Rep Neurol Med. 2014; 2014:237064. Epub 2014 Apr 17. PMID: 24822136. Abstract
Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine. Serra A, Skelly MM, Jacobs JB, Walker MF, Cohen JA Neurology. 2014 Jun 6. PMID: 24907233. Abstract
Central motor conduction time may predict response to fampridine in patients with multiple sclerosis. Zeller D, Reiners K, Bräuninger S, Buttmann M J Neurol Neurosurg Psychiatry. 2013 Dec 19. PMID: 24357684. Abstract
Innovation at RUSH Rush University, Dec 2010 Accessed on 16 Aug 2014 from http://www.rushu.rush.edu/servlet/BlobServer?blobcol=urlfile&blobtable=document&blobkey=id&blobwhere=1291639480369&blobheader=application%2Fpdf&blobnocache=true.
Rush University Medical Center Sells AMPYRA® Royalty Rights to DRI Capital Managed Fund for Approximately $42 Million MarketWatch, 12 Aug 2014 Accessed on 16 Aug 2014 from http://www.marketwatch.com/story/correcting-and-replacingrush-university-medical-center-sells-ampyra-royalty-rights-to-dri-capital-managed-fund-for-approximately-42-million-2014-08-12.
Potentiation of High Voltage-Activated Calcium Channels by 4-Aminopyridine Depends upon Subunit Composition. Li L, Li D-P, Chen S-R, Chen J, Hu H, Pan H-L Mol Pharmacol. 2014 Sep 29. PMID: 25267719. Abstract
Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis. Birnbaum G, Iverson J Neurology. 2014 Sep 26. PMID: 25261505. Abstract
A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis. Goodman AD, Brown TR, Schapiro RT, Klingler M, Cohen R, Blight AR Int J MS Care. 2014 Fall; 16(3):153-60. PMID: 25337058. Abstract
Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program. Crayton H, Sidovar M, Wulf S, Guo A Patient. 2014 Dec 5. PMID: 25475652. Abstract
Acorda Announces Initiation of Phase 3 Clinical Trial for Dalfampridine in Post-Stroke Walking Deficits Acorda Therapeutics, 15 Dec 2014 Accessed on 23 Dec 2014 from http://ir.acorda.com/investors/investor-news/investor-news-details/2014/Acorda-Announces-Initiation-of-Phase-3-Clinical-Trial-for-Dalfampridine-in-Post-Stroke-Walking-Deficits/default.aspx.
Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis. Jara M, Sidovar MF, Henney HR Ther Clin Risk Manag. 2015; 11:1-7. Epub 2014 Dec 16. PMID: 25565851. Abstract
Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis. Kantor D, Chancellor MB, Snell CW, Henney Iii HR, Rabinowicz AL Postgrad Med. 2015 Jan 6:1-5. PMID: 25560174. Abstract
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials. Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, Henney HR, Blight AR, on behalf of the MS-F203, MS-F204, and Extension Study Investigators, on behalf of the MS-F203 MS-F204 and Extension Study Investigators Mult Scler. 2015 Jan 12. PMID: 25583832. Abstract
Effects of functional electrical stimulation on gait function and quality of life for people with multiple sclerosis taking dalfampridine. Mayer L, Warring T, Agrella S, Rogers HL, Fox EJ Int J MS Care. 2015 Jan-Feb; 17(1):35-41. PMID: 25741225. Abstract
Dalfampridine in hereditary spastic paraplegia: a prospective, open study. Béreau M, Anheim M, Chanson J-B, Tio G, Echaniz-Laguna A, Depienne C, Collongues N, De Sèze J J Neurol. 2015 Mar 26. Epub 2015 Mar 26. PMID: 25808501. Abstract
Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial. Hupperts R, Lycke J, Short C, Gasperini C, McNeill M, Medori R, Tofil-Kaluza A, Hovenden M, Mehta LR, Elkins J Mult Scler. 2015 Apr 28. PMID: 25921050. Abstract
Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis. (MOBILE) ClinicalTrials.gov, 17 Jul 2014 Accessed on 5 May 2015 from https://www.clinicaltrials.gov/ct2/show/NCT01597297.
Biogen Idec Becomes Biogen Biogen, 23 Mar 2015 Accessed on 7 Apr 2015 from http://biogen.newshq.businesswire.com/press-release/corporate/biogen-idec-becomes-biogen.
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial. Yapundich R, Applebee A, Bethoux F, Goldman MD, Hutton GJ, Mass M, Pardo G, Klingler M, Henney HR, Blight AR, et al. Int J MS Care. 2015 May-Jun; 17(3):138-45. PMID: 26052259. Abstract
Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders. Lo AC, Ruiz JA, Koenig CM, Anderson BM, Olson KM, Triche EW J Neurol Sci. 2015 Jun 8. PMID: 26139339. Abstract
Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients. Pavsic K, Pelicon K, Ledinek A H, Sega S Clin Neurol Neurosurg. 2015 Aug 28; 139:35-40. PMID: 26363365. Abstract
Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine). Keune PM, Cocks AJ, Young WR, Burschka JM, Hansen S, Hofstadt-van Oy U, Oschmann P, Muenssinger J BMC Neurol. 2015; 15(1):171. Epub 2015 Sep 24. PMID: 26400041. Abstract
Ampyra for Optic Neuritis in MS ClinicalTrials.gov, 14 Feb 2014 Accessed on 6 Oct 2015 from https://www.clinicaltrials.gov/ct2/show/NCT01337986.
No Help from Dalfampridine in MS-Related Optic Neuritis Blum K, MedPage Today, 29 Sep 2015 Accessed on 6 Oct 2015 from http://www.medpagetoday.com/MeetingCoverage/ANA/53801.
Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine. Macdonell R, Nagels G, Laplaud D-A, Pozzilli C, de Jong B, Martins da Silva A, Nicholas R, Lechner-Scott J, Gaebler JA, Agarwal S, et al. Mult Scler. 2015 Oct 7. PMID: 26447066. Abstract
Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment. Jensen H, Ravnborg M, Mamoei S, Dalgas U, Stenager E Mult Scler. 2014 May 22. PMID: 24852920. Abstract
Effects of Dalfampridine Extended-Release Tablets on 6-Minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-Blind, Placebo-Controlled Trial. Applebee A, Goodman AD, Mayadev AS, Bethoux F, Goldman MD, Klingler M, Blight AR, Carrazana EJ Clin Ther. 2015 Nov 9. PMID: 26565077. Abstract
Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis. Fjeldstad C, Suárez G, Klingler M, Henney HR, Rabinowicz AL, Pardo G Int J MS Care. 2015 Nov-Dec; 17(6):275-83. PMID: 26664333. Abstract
Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis. Savin Z, Lejbkowicz I, Glass-Marmor L, Lavi I, Rosenblum S, Miller A J Neurol Sci. 2016 Jan 15; 360:102-9. Epub 2015 Dec 02. PMID: 26723984. Abstract
Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States. Jara M, Aquilina T, Aupperle P, Rabinowicz AL Drug Healthc Patient Saf. 2015; 7:169-74. Epub 2015 Dec 15. PMID: 26719727. Abstract
Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern. Zörner B, Filli L, Reuter K, Kapitza S, Lörincz L, Sutter T, Weller D, Farkas M, Easthope CS, Czaplinski A, et al. Mult Scler. 2016 Jan 13. PMID: 26762672. Abstract
Changes in Cognitive Processing Speed, Mood, and Fatigue in an Observational Study of Persons With Multiple Sclerosis Treated With Dalfampridine-ER. Triche EW, Ruiz JA, Olson KM, Lo AC Clin Neuropharmacol. 2016 Jan 25. PMID: 26818040. Abstract